Rajesh Behl is an Oncology physician affiliated with Sutter Health. OpenAlex indexes 17 publications with 429 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2001 Dwight Way
Berkeley, CA 947042608
Telephone
510-204-1591Registry record last updated 8 Jul 2007.
Industry payments
61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202549 payments$35,383openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202536 payments$33,806openpaymentsdata.cms.gov ↗
- Karyopharm Therapeutics Inc.Program year202519 payments$26,808openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.1%Kinase inhibitor13%Jakafi36%Imbruvica22%Brukinsa14%Calquence12%Imatinib Mesylate10%Iclusig6%Part D<11 patientsThalidomide Analog9%Lenalidomide51%Revlimid49%Part D≥16 patients+ 5 more classes in this area
Dermatology
20.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20.5%Acyclovir100%Part D≥74 patientsBlood & clotting
10.6%Factor Xa inhibitor9%Xarelto53%Eliquis47%Part D≥19 patientsThrombopoietin Receptor Agonist0.9%Promacta100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CT-412 ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
Clinical Lymphoma Myeloma & Leukemia
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Milani, MD
Sutter Health
Roger Winkle, MD
Sutter Health
Powell Jose, MD
Sutter Health
David Bonovich, MD
Sutter Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”